Beating
Canine
Cancer
Backed by science
Led by compassion
Dog Owners
Click below to learn about our new cancer treatments being developed for dogs, how they work, and ways your dog may be able to access them.
Vets
Click below to learn about our investigational medicines for canine cancer patients, including the science, clinical trials and compassionate use.
The challenge
Cancer is one of the leading causes of death in dogs. Current treatment options have major limitations, and many dogs still need better ways to treat their cancer.
Our approach
CaniVax develops new cancer medicines for dogs by translating advances in modern human cancer medicine. Our programmes include both oral cancer drugs and cancer vaccines.
The science
Our work is grounded in cancer biology, genetics and immunology. We use these advances to develop and test new treatments specifically for canine cancer patients.
Contact us for further information and access options.
A science-led approach to canine cancer
Most existing cancer treatments rely on old-fashioned chemotherapy which often causes unpleasant side-effects which make your dog feel even worse.
CaniVax aims to develop new vaccines that educate the dog's natural immune system to target antigens present on the tumours.
As a result, vaccination allows the immune system to distinguish cancer cells clearly from healthy cells, limiting the unpleasant side effects and killing the cancer cells.
CaniVax's approach is based on identifying tumour-specific antigens present on cancer cells and using them to guide immune recognition. By making cancer more visible to the immune system, our vaccine strategy provides a more focused immune response.
In practical terms, our approach follows four deliberate steps:
1. Identify antigens that are specific to the dog's cancer
2. Confirm which of these antigens can arm your dog's immune response
3. Engineer vaccines that present these antigens to your dog's immune system
4. Vaccinate your dog and measure the cancer-specific immune response
Vaccine development with regulatory body guidance
CaniVax applies robust scientific platforms to carefully guide its vaccine design, working in collaboration with veterinary professionals and regulatory bodies.
"Our goal is to develop a new range of effective canine cancer vaccines, providing owners with better therapeutic options than those that are currently available." - CaniVax CEO
Latest News
CaniVax™ Announces appointment of Dr Thu Nguyen to lead its canine cancer vaccine programme
OXFORD, UK; 14 July 2026 – CaniVax™ Limited, the leader in developing novel therapeutics to treat canine cancer, has today announced the appointment of Dr Thu Nguyen to lead its canine cancer vaccine programme. Dr Nguyen is a highly experienced…
Cancer Treatment Is Changing. The Immune System Offers New Possibilities.
Cancer treatment is evolving as scientists learn more about the biology of cancer and the immune system. While traditional therapies often focus on directly targeting tumour growth, newer approaches are exploring whether the immune system itself may become part of…
Cancer Leaves a Trail. Science Is Finally Learning to Follow It
Cancer is not invisible to the immune system. The real question is why it is not always recognised. Immunopeptidomics offers a way to look directly at what cancer cells are showing to the immune system, and what may be going…
Register your interest
CaniVax vaccines are being developed through robust and rigorous scientific platforms, extensively validated and fine-tuned for canine cancer.
If you would like to receive further details on how we can help your pet, please provide your details below. One of our experts will respond to you shortly.
Photo credit © Adrian Baughan - Oxford Dog Photography.